Printer Friendly

MARION MERRELL DOW AND RHONE-POULENC RORER REACH AGREEMENT TO SETTLE DISPUTES REGARDING ANTIHYPERTENSIVE DRUGS

 MARION MERRELL DOW AND RHONE-POULENC RORER REACH AGREEMENT
 TO SETTLE DISPUTES REGARDING ANTIHYPERTENSIVE DRUGS
 COLLEGEVILLE, Pa.,/KANSAS CITY, Mo., Aug. 5 /PRNewswire/ -- Marion Merrell Dow Inc. (NYSE: MKC) and Rhone-Poulenc Rorer Pharmaceuticals Inc. (NYSE: RPR) announced today that a lawsuit filed by Marion Merrell Dow, and a planned countersuit by Rhone-Poulenc Rorer, have been settled.
 In their respective claims, Marion Merrell Dow alleged that Rhone- Poulenc Rorer, based on currently available data, was inappropriately implying generic substitutability (bioequivalence) of its Dilacor(TM) XR for Cardizem(R) CD, while Rhone-Poulenc Rorer alleged that Marion Merrell Dow was inappropriately implying that Dilacor(TM) XR was not as potent (bioavailable) as Cardizem(R) CD.
 In the terms of the settlement, Rhone-Poulenc Rorer acknowledged that Dilacor(TM) XR is not generically substitutable for Cardizem(R) CD, while Marion Merrell Dow acknowledged, based on current available data, that the two products offer similar bioavailability, and that both products are safe and effective antihypertensive agents.
 Both companies agreed to direct their future marketing efforts in accord with this agreement.
 Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of human pharmaceuticals. RPR had annual sales of $3.8 billion in 1991 and plans to invest more than $500 million in research and development in 1992.
 Headquartered in Kansas City, Marion Merrell Dow is a global pharmaceutical company involved in the discovery, development, manufacture and marketing of prescription and over-the-counter products. Marion Merrell Dow markets its products around the world, predominantly in North America, Europe and the Pacific Basin.
 -0- 8/5/92
 /CONTACT: David M. Thompson or Richard M. Johnson of Marion Merrell Dow, 816-966-4000; or Bob Pearson of Rhone-Poulenc Rorer Pharmaceuticals, 215-454-3872/
 (MKC RPR) CO: Marion Merrell Dow Inc.; Rhone-Poulenc Rorer Pharmaceuticals Inc. ST: Missouri, Pennsylvania IN: MTC SU:


BB-MC -- DV002 -- 7134 08/05/92 13:32 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 5, 1992
Words:309
Previous Article:ESSEX CORPORATION REPORTS SECOND QUARTER 1992 RESULTS
Next Article:EASTEX ANNOUNCES SECOND QUARTER 1992 EARNINGS
Topics:


Related Articles
MILES INC. AND RHONE-POULENC RORER SETTLE PATENT DISPUTE
RHONE-POULENC RORER FILES LAWSUIT AGAINST MARION MERRELL DOW ALLEGING FALSE AND MISLEADING PROMOTION
MARION MERRELL DOW FILES SUIT OVER COMPETITOR'S CLAIMS THAT DRUGS ARE SIMILAR
RHONE-POULENC RORER FILES FOR PELIMINARY INJUNCTION AGAINST MARION MERRELL DOW, ALLEGING FALSE AND MISLEADING PROMOTION
MARION MERRELL DOW AND TANABE SEIYAKU FILE INTERNATIONAL TRADE COMPLAINT AGAINST CARDIZEM IMITATORS
MARION MERRELL DOW AND TANABE SEIYAKU ANNOUNCE INTERNATIONAL TRADE COMMISSION INVESTIGATION OF CARDIZEM IMITATORS
GENETICS INSTITUTE PLEASED WITH BAXTER AND RHONE-POULENC RORER FACTOR VIII PATENT SETTLEMENT
BAXTER, RHONE-POULENC RORER RESOLVE ALL DISPUTES INVOLVING FACTOR VIII:C PATENTS; SIGN PURCHASING AGREEMENT FOR BAXTER PRODUCTS
U.S. INTERNATIONAL TRADE COMMISSION REJECTS CLAIM FILED BY MARION MERRELL DOW AND TANABE
RHONE-POULENC RORER S.A. FILES PATENT INFRINGEMENT LAWSUIT AGAINST BRISTOL-MYERS SQUIBB REGARDING TAXOL(R)

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters